Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer
This course contains the webinar, a handout, and continuing education credit (CME and CMLE).
Description:
This webinar is based on new joint consensus recommendations from the Association for Molecular Pathology for the analytical validation and reporting of tumor mutational burden (TMB) testing as a potential predictive biomarker for immune checkpoint inhibitor (ICI) therapies. The AMP TMB Working Group, including organizational representation from the American Society of Clinical Oncology (ASCO), College of American Pathologists (CAP), and Society for Immunotherapy of Cancer (SITC), was established to assess existing laboratory practices and develop evidence-based standards for the analytical validation and reporting of clinical TMB testing. The recommendations, which are intended to be a reference guide based on scientific literature, observational survey data, and the professional experience of the Working Group’s subject matter experts, encompass pre-analytical, analytical, and post-analytical factors of TMB analysis, and emphasize the importance of comprehensive methodological descriptions in publications to allow comparability between assays.
Learning Objectives:
- Identify current challenges related to the adoption of TMB testing.
- Discuss new consensus recommendations for TMB assay validation and test reporting.
Speaker
Larissa V. Furtado, MD
St. Jude Children's Research Hospital
Moderator
Susan J. Hsiao, MD, PhD
Columbia University
Vagelos College of Physicians and Surgeons
Duration: 1 Hour
Level of Instruction: Basic
Live Webinar: September 10, 2024
Date Recorded: July 29. 2024
Planned and coordinated by the Clinical Practice Committee and Training and Education Committee
Continuing Education Credit Information
CME credit: 1.0
CMLE credit: 1.0
Last day to claim credit: March 20, 2027
Accreditation Statements
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
CMLE
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Note: Members of AMP can access this webinar at no cost. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
